Recent discussions on X about BioCryst Pharmaceuticals (BCRX) have centered around the company's strong growth prospects, particularly following their presentation at the Cantor Global Healthcare Conference 2025. Many users have highlighted the impressive revenue surge of 49% in Q2, driven by the success of ORLADEYO, a key drug for rare diseases, sparking optimism about the company's pipeline. The buzz reflects a keen interest in how BioCryst is positioning itself in the competitive biotech landscape.
Additionally, some conversations on X have touched on analyst ratings, with a consensus 'Moderate Buy' from multiple firms, as noted in recent web reports. There’s a mix of excitement and caution, as investors debate the stock’s volatility and potential upside, with some pointing to significant growth opportunities. This dynamic discussion keeps BioCryst a focal point for those tracking biotech developments.
Note: This discussion summary was generated from an AI condensation of post data.
BioCryst Pharmaceuticals Insider Trading Activity
BioCryst Pharmaceuticals insiders have traded $BCRX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BCRX stock by insiders over the last 6 months:
- THERESA HEGGIE sold 70,000 shares for an estimated $595,868
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BioCryst Pharmaceuticals Hedge Fund Activity
We have seen 166 institutional investors add shares of BioCryst Pharmaceuticals stock to their portfolio, and 130 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 4,692,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $42,040,320
- AVORO CAPITAL ADVISORS LLC removed 4,200,000 shares (-48.3%) from their portfolio in Q2 2025, for an estimated $37,632,000
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 4,084,403 shares (+2103.7%) to their portfolio in Q2 2025, for an estimated $36,596,250
- ASSENAGON ASSET MANAGEMENT S.A. added 3,606,566 shares (+25631.2%) to their portfolio in Q2 2025, for an estimated $32,314,831
- UBS GROUP AG added 3,211,465 shares (+133.6%) to their portfolio in Q2 2025, for an estimated $28,774,726
- MORGAN STANLEY added 3,032,005 shares (+132.0%) to their portfolio in Q2 2025, for an estimated $27,166,764
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 2,954,777 shares (-36.3%) from their portfolio in Q1 2025, for an estimated $22,160,827
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BioCryst Pharmaceuticals Government Contracts
We have seen $15,416,286 of award payments to $BCRX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN)): $13,877,673
- BULK ORLADEYO PHARMACEUTICAL: $394,853
- BULK ORDER ORLADEYO FOR VETERAN CARE.: $382,300
- BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO).: $379,939
- BEROTRALSTAT HCL 150MG CAP,ORAL TRADE NAME: ORLADEYO 150MG CAP: $379,348
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BioCryst Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $BCRX in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 08/04/2025
- B of A Securities issued a "Buy" rating on 07/01/2025
- RBC Capital issued a "Outperform" rating on 06/30/2025
- Wedbush issued a "Outperform" rating on 06/30/2025
- JP Morgan issued a "Overweight" rating on 05/06/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/06/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/29/2025
To track analyst ratings and price targets for BioCryst Pharmaceuticals, check out Quiver Quantitative's $BCRX forecast page.
BioCryst Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $BCRX recently. We have seen 8 analysts offer price targets for $BCRX in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $17.0 on 08/04/2025
- Tazeen Ahmad from B of A Securities set a target price of $15.0 on 07/01/2025
- Brian Abrahams from RBC Capital set a target price of $13.0 on 06/30/2025
- Laura Chico from Wedbush set a target price of $18.0 on 06/30/2025
- Gena Wang from Barclays set a target price of $11.0 on 05/07/2025
- Jessica Fye from JP Morgan set a target price of $13.0 on 05/06/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $30.0 on 05/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
